Next Article in Journal
Long-Term Surgical Outcome of Class A and B Tympanomastoid Paragangliomas
Previous Article in Journal
The Gut Connection: Exploring the Possibility of Implementing Gut Microbial Metabolites in Lymphoma Treatment
 
 
Article
Peer-Review Record

Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors

Cancers 2024, 16(8), 1465; https://doi.org/10.3390/cancers16081465
by Sara Mokbel 1, Giuilia Baciarello 2, Pernelle Lavaud 3, Aurelius Omlin 4, Fabio Calabrò 5, Richard Cathomas 5, Stefanie Aeppli 6, Pauline Parent 7, Patrizia Giannatempo 8, Kira-Lee Koster 6, Naara Appel 9, Philippe Gonnet 9, Gesuino Angius 2, Petros Tsantoulis 9, Hendrick-Tobias Arkenau 10, Carlo Cattrini 11, Carlo Messina 12, Jean Zeghondy 3, Cristina Morelli 13, Yohann Loriot 3, Vincenzo Formica 13 and Anna Patrikidou 3,*add Show full author list remove Hide full author list
Reviewer 1:
Reviewer 2: Anonymous
Cancers 2024, 16(8), 1465; https://doi.org/10.3390/cancers16081465
Submission received: 6 March 2024 / Revised: 2 April 2024 / Accepted: 8 April 2024 / Published: 11 April 2024
(This article belongs to the Special Issue Progress in the Systemic Therapy of Urological Oncology)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

Title - concise and clear - No Remarks

Abstract - clearly defining the essence of the study - 

row 46 - IO cohort? - abbreviation needs clarification - MINOR

introduction - elegant presentation on the current knowledge on the subject, and the different approaches for ICI inclusion in therapy of a/m urothelial cancer 

row 70 PDL-1 ? typo? Minor

row 87 - IO ? - needs clarification

Material and Methods - No Remarks

Results 

 

row 141 - "Median OS was similar in the D, V and cohorts (15.3 months vs 14.2 months vs 14.6 months, p=0.889)" - third cohort is missing, what is this third cohort? - MAJOR   table 1 - primary tumor location - Upper Tract (Bladder) ???

 

Lower tract (ureter, renal pelvis)???? - MAJOR - serious discrepancy   Type of chemo treatment (n, %) - row misalignment - MAJOR

 

Pretreatment performance status (ECOG) (n,%) - extremely high rate of unknown in chemo group (52 %) - potential significant source of bias in OS assessment  - needs comment - Major

 

Circulating inflammatory markers (median, range)  - row misalignment - MAJOR Radiological response (n, %) -  extremely high rate of non-evaluable in chemo group (55%) - potential significant source of bias in PFS assessment  - needs comment - Major   Discussion - No remarks - nicely implementing the authors results into the contemporary literature and strongly substantiating their conclusions

Author Response

please see the attachment 

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

The manuscript "Development and validation of the U-IPI index to predict out- comes in advanced/metastatic urothelial cancer patients receiving immune checkpoint inhibitors" aims to develop and validate an immune prognostic index for  advanced/metastatic urothelial cancer. The manuscript brings novelty to urothelial cancer prognosis and treatment, due to the identification of an inflammatory profile able to stratify the patients.

In the abstract, provide the acronym for LDH.

The discussion should be improved. The authors could discuss more the results otained and the inflammatory parameters with the literature. 

 

Author Response

Please see the attachment. 

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

Comments and Suggestions for Authors

the authors has taken into account this reviewer`s recommendations 

Back to TopTop